The role of erythropoietin in the pathogenesis and treatment of iron deficiency anemia during pregnancy and in the postpartum period

Iron deficiency anemia (IDA) is a very common pathological condition during pregnancy and the postpartum period. In the structure of hematological diseases in pregnant women, anemias account for about 90% and in most cases are iron deficient [3, 17, 19]. In the third trimester of pregnancy and in the early postpartum period, almost every woman has a latent iron deficiency, and 30–40% develop IDA [4, 15, 16, 20, 26]. According to the Ministry of Health of the Russian Federation, the frequency of IDA in Russia has increased 6.3 times over the past ten years, and in St. Petersburg - almost 2 times.

The development of anemia during pregnancy is due to an imbalance of iron in the body and is associated with its increased costs for creating a fetoplacental complex, an increase in iron metabolism and a redistribution of this trace element in favor of the fetus. Iron deficiency in the body of pregnant women and women in childbirth is associated with inadequate replacement of losses due to alimentary and mobilized iron.